CW2IP2: Imaging and Diagnostic Assessments

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
University of Pennsylvania
Study ID
NCT06083467
Status
Recruiting

Conditions

  • Tauopathies

Eligibility Criteria

Sex
ALL
Age
40 Years - 85 Years
Healthy Volunteers
Accepted

Interventions

  • Brain MRI Scan — DIAGNOSTIC_TEST
    MRI scan of the brain
  • Neurologic exam — BEHAVIORAL
    Neurologic exam and assessments, including video interview

Study Details

This current protocol will provide the key data to help determine the specificity of our to-be-developed radiotracers by implementing a multi-site diagnostic assessment core and PET imaging of A-beta amyloid (may be completed at some sites as part of another protocol) that is commonly deposited in the brains of people with Parkinson's Disease (PD), Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP) or Frontotemporal Dementia (FTD) as well as healthy controls. This multicenter U19 grant is centered at U Pennsylvania (U Penn) (PI: Robert Mach) in collaboration with U Pittsburgh (Pitt), Yale University, U of California at San Francisco (UCSF) and Washington University in St. Louis (WU). U Penn will act as the single IRB of Record (sIRB) for this multi-center project and subjects will be recruited from all sites.

Key Dates

Start date
Jul 20, 2023
Status verified
Nov 2025
Primary completion
Jul 31, 2028
Completion
Jul 31, 2028

Study Design

Enrollment
94 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Other: Diagnostic Assessments
    Subjects may receive a brain MRI and neurological exam with diagnostic assessments.

Primary Outcome Measure

Disease diagnosis [ Time Frame: 8 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of PennsylvaniaPhiladelphiaPennsylvania19104
Erin Schubert
215-662-3041
Ilya Nasrallah, MD, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Philadelphia, PA

Related Studies